Wei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Liu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Junjun Shao
State Key Laboratory for Animal Disease Control and Prevention, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China
7 shared publications - Huiyun Chang
State Key Laboratory for Animal Disease Control and Prevention, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China
6 shared publications Sicheng Yang
State Key Laboratory for Animal Disease Control and Prevention, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China
5 shared publicationsGuanglei Zhang
State Key Laboratory for Animal Disease Control and Prevention, Gansu Province Research Center for Basic Disciplines of Pathogen Biology, OIE/China National Foot-and-Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, China
4 shared publicationsHuiyun Chang
State Key Laboratory of Animal Disease Control and Prevention, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China
4 shared publicationsHuihui Yang
State Key Laboratory of Veterinary Etiological Biology, National Foot-and-Mouth Diseases Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in Applied Microbiology and Biotechnology
A bioluminescence immunosensor using engineered antibody for quantitative detection of African swine fever virus
- 9 November 2026
- Published by Springer Nature in Applied Microbiology and Biotechnology
Open AccessA bioluminescence immunosensor using engineered antibody for quantitative detection of African swine fever virus
- Open Access
- 9 January 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (1) , 36
Molecular Mechanism of VSV-Vectored ASFV Vaccine Activating Immune Response in DCs
The vesicular stomatitis virus (VSV)-vectored African swine fever virus (ASFV) vaccine can induce efficient immune response, but the potential mechanism remains unsolved. In order to investigate the efficacy of recombinant viruses (VSV-p35, VSV-p72)-mediated dendritic cells (DCs) maturation and the mechanism of inducing T-cell immune response, the functional effects of recombinant viruses on DC activation and target antigens presentation were explored in this study. The results showed that surface-marked molecules (CD80, CD86, CD40, and MHC-II) and secreted cytokines (IL-4, TNF-α, IFN-γ) were highly expressed in the recombinant virus-infected DCs. In addition, the co-culture results of recombinant virus-treated DCs with naive T cells showed that the Th1- and Th17-type responses were effectively activated. Taken together, the study indicated that the VSV-vectored ASFV vaccine activated the maturation of DCs and the Th1- and Th17-type immune response, which provided a theoretical basis for the development of novel ASF vaccines.
- 9 January 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (1) , 36
Open AccessMolecular Mechanism of VSV-Vectored ASFV Vaccine Activating Immune Response in DCs
The vesicular stomatitis virus (VSV)-vectored African swine fever virus (ASFV) vaccine can induce efficient immune response, but the potential mechanism remains unsolved. In order to investigate the efficacy of recombinant viruses (VSV-p35, VSV-p72)-mediated dendritic cells (DCs) maturation and the mechanism of inducing T-cell immune response, the functional effects of recombinant viruses on DC activation and target antigens presentation were explored in this study. The results showed that surface-marked molecules (CD80, CD86, CD40, and MHC-II) and secreted cytokines (IL-4, TNF-α, IFN-γ) were highly expressed in the recombinant virus-infected DCs. In addition, the co-culture results of recombinant virus-treated DCs with naive T cells showed that the Th1- and Th17-type responses were effectively activated. Taken together, the study indicated that the VSV-vectored ASFV vaccine activated the maturation of DCs and the Th1- and Th17-type immune response, which provided a theoretical basis for the development of novel ASF vaccines.
- Open Access
- 1 January 2025
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 2025 (1) , 8023572
Discovery of a Structurally Stable Immunodominant Region in ASFV p30 C‐Terminus Using a Panel of Monoclonal Antibodies
African swine fever (ASF) is a lethal hemorrhagic viral disease of pigs with devastating global socioeconomic impacts. Due to the absence of a safe and effective vaccine, early surveillance and precise diagnostics are critical for ASF prevention and control. The ASF virus (ASFV) p30 protein, one of the most immunogenic early‐expressed antigens during infection, is a prime target for diagnostic assays and subunit vaccines. Its comprehensive antigenic characterization remains crucial for rational vaccine design. In this study, we generated a panel of 20 monoclonal antibodies (MAbs) against the ASFV p30 protein, classifying them into 11 groups based on epitope specificity. MAbs from six groups (subgroups I‐1, I‐2, and II‐1, as well as groups III, IV, and V, collectively comprising 15 MAbs) recognized six distinct epitopes within the C‐terminus of p30 (137–194 aa), while MAb 16‐5E7E8 (subgroup II‐2) recognized a distinct epitope within residues 154–190. The p30 C‐terminus (137–194 aa) demonstrated structural stability under denaturing conditions (SDS–PAGE and western blot [WB]) and was identified as an immunodominant region through its reactivity with ASFV‐positive sera. Notably, MAbs targeting this immunodominant region exhibited modest neutralizing activity, whereas those binding to other regions showed no neutralizing activity. Furthermore, MAb Q4‐1F10B7 (group VI) recognized a linear epitope “ 116 TSSFETLFEQ 125 ,” MAbs Q1‐1G4B2 (group VIII) and Q8‐4F9F3 (group IX) recognized conformation‐dependent epitopes, and MAb 5‐1C8B6 (group VII) likely recognized an aberrant or non‐native form of the p30 protein. These results expand the epitope landscape of p30 protein and lay a foundation for ASF diagnosis and vaccine research.
- 1 January 2025
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 2025 (1) , 8023572
Open AccessDiscovery of a Structurally Stable Immunodominant Region in ASFV p30 C‐Terminus Using a Panel of Monoclonal Antibodies
African swine fever (ASF) is a lethal hemorrhagic viral disease of pigs with devastating global socioeconomic impacts. Due to the absence of a safe and effective vaccine, early surveillance and precise diagnostics are critical for ASF prevention and control. The ASF virus (ASFV) p30 protein, one of the most immunogenic early‐expressed antigens during infection, is a prime target for diagnostic assays and subunit vaccines. Its comprehensive antigenic characterization remains crucial for rational vaccine design. In this study, we generated a panel of 20 monoclonal antibodies (MAbs) against the ASFV p30 protein, classifying them into 11 groups based on epitope specificity. MAbs from six groups (subgroups I‐1, I‐2, and II‐1, as well as groups III, IV, and V, collectively comprising 15 MAbs) recognized six distinct epitopes within the C‐terminus of p30 (137–194 aa), while MAb 16‐5E7E8 (subgroup II‐2) recognized a distinct epitope within residues 154–190. The p30 C‐terminus (137–194 aa) demonstrated structural stability under denaturing conditions (SDS–PAGE and western blot [WB]) and was identified as an immunodominant region through its reactivity with ASFV‐positive sera. Notably, MAbs targeting this immunodominant region exhibited modest neutralizing activity, whereas those binding to other regions showed no neutralizing activity. Furthermore, MAb Q4‐1F10B7 (group VI) recognized a linear epitope “ 116 TSSFETLFEQ 125 ,” MAbs Q1‐1G4B2 (group VIII) and Q8‐4F9F3 (group IX) recognized conformation‐dependent epitopes, and MAb 5‐1C8B6 (group VII) likely recognized an aberrant or non‐native form of the p30 protein. These results expand the epitope landscape of p30 protein and lay a foundation for ASF diagnosis and vaccine research.
- 25 September 2024
- Published by Elsevier in Antiviral Research
- Vol. 231, 106011
Dendritic cell-based biomimetic nanoparticles for foot-and-mouth disease induce robust cellular immunity
- 25 September 2024
- Published by Elsevier in Antiviral Research
- Vol. 231, 106011
Dendritic cell-based biomimetic nanoparticles for foot-and-mouth disease induce robust cellular immunity
- Open Access
- 19 September 2024
- Published by MDPI AG in Preprints.org
Molecular Mechanism of VSV Recombinant ASFV Antigen Gene Activating Immune Response of DCs in Mice
The VSV recombinant ASFV antigen gene live vector vaccines can induce efficient immune response, but the detailed mechanism remains unsolved yet. In order to investigate the efficacy of recombinant viruses (VSV-p35, VSV-p72) mediated dendritic cells (DCs) maturation and the mechanism of inducing T cells immune response, the functional effects of recombinant viruses to DCs activation and target antigens presentation were explored in this study. The results showed that surface marked molecules (CD80, CD86, CD40, and MHC-II) and secreted cytokines (IL-4, TNF-α, IFN-γ) were highly expressed in DCs that treated with recombinant viruses. The mixed lymphocyte reaction experiment results showed that the naive lymphocytes and polarized the CD4+T lymphocytes towards Th1 and Th17 cells were effectively activated when DCs were treated with recombinant viruses. In conclusion, the study indicated that VSV recombinant ASFV antigen gene live vector vaccine activated the maturation of DCs and the Th1 and Th17 type immune response, which provided a theoretical basis for the development of novel ASF vaccines.
- 19 September 2024
- Published by MDPI AG in Preprints.org
Open AccessMolecular Mechanism of VSV Recombinant ASFV Antigen Gene Activating Immune Response of DCs in Mice
The VSV recombinant ASFV antigen gene live vector vaccines can induce efficient immune response, but the detailed mechanism remains unsolved yet. In order to investigate the efficacy of recombinant viruses (VSV-p35, VSV-p72) mediated dendritic cells (DCs) maturation and the mechanism of inducing T cells immune response, the functional effects of recombinant viruses to DCs activation and target antigens presentation were explored in this study. The results showed that surface marked molecules (CD80, CD86, CD40, and MHC-II) and secreted cytokines (IL-4, TNF-α, IFN-γ) were highly expressed in DCs that treated with recombinant viruses. The mixed lymphocyte reaction experiment results showed that the naive lymphocytes and polarized the CD4+T lymphocytes towards Th1 and Th17 cells were effectively activated when DCs were treated with recombinant viruses. In conclusion, the study indicated that VSV recombinant ASFV antigen gene live vector vaccine activated the maturation of DCs and the Th1 and Th17 type immune response, which provided a theoretical basis for the development of novel ASF vaccines.
- Open Access
- 2 August 2024
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 108 (1) , 1-12
Development of plate-type and tubular chemiluminescence immunoassay against African swine fever virus p72
African swine fever (ASF) is a highly contagious and fatal viral disease that has caused huge economic losses to the pig and related industries worldwide. At present, rapid, accurate, and sensitive laboratory detection technologies are important means of preventing and controlling ASF. However, because attenuated strains of African swine fever virus (ASFV) are constantly emerging, an ASFV antibody could be used more effectively to investigate the virus and control the disease on pig farms. The isolation of ASFV-specific antibodies is also essential for the diagnosis of ASF. Therefore, in this study, we developed two chemiluminescence immunoassays (CLIAs) to detect antibodies directed against ASFV p72: a traditional plate-type blocking CLIA (p72-CLIA) and an automatic tubular competitive CLIA based on magnetic particles (p72-MPCLIA). We compared the diagnostic performance of these two methods to provide a feasible new method for the effective prevention and control of ASF and the purification of ASFV. The cut-off value, diagnostic sensitivity (Dsn), and diagnostic specificity (Dsp) of p72-CLIA were 40%, 100%, and 99.6%, respectively, in known background serum, whereas those of p72-MPCLIA were 36%, 100%, and 99.6%, respectively. Thus, both methods show good Dsn, Dsp, and repeatability. However, when analytical sensitivity was evaluated, p72-MPCLIA was more sensitive than p72-CLIA or a commercial enzyme-linked immunosorbent assay. More importantly, p72-MPCLIA reduced the detection time to 15 min and allowed fully automated detection. In summary, p72-MPCLIA showed superior diagnostic performance and offered a new tool for detecting ASFV infections in the future. Key points: • Two chemiluminescence immunoassay (plate-type CLIA and tubular CLIA) methods based on p72 monoclonal antibody (mAb) were developed to detect ASFV antibody. • Both methods show good diagnostic performance (Dsn (100%), Dsp (99.6%), and good repeatability), and p72-MPCLIA detects antibodies against ASFV p72 with high efficiency in just 15 min.
- 2 August 2024
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 108 (1) , 1-12
Open AccessDevelopment of plate-type and tubular chemiluminescence immunoassay against African swine fever virus p72
African swine fever (ASF) is a highly contagious and fatal viral disease that has caused huge economic losses to the pig and related industries worldwide. At present, rapid, accurate, and sensitive laboratory detection technologies are important means of preventing and controlling ASF. However, because attenuated strains of African swine fever virus (ASFV) are constantly emerging, an ASFV antibody could be used more effectively to investigate the virus and control the disease on pig farms. The isolation of ASFV-specific antibodies is also essential for the diagnosis of ASF. Therefore, in this study, we developed two chemiluminescence immunoassays (CLIAs) to detect antibodies directed against ASFV p72: a traditional plate-type blocking CLIA (p72-CLIA) and an automatic tubular competitive CLIA based on magnetic particles (p72-MPCLIA). We compared the diagnostic performance of these two methods to provide a feasible new method for the effective prevention and control of ASF and the purification of ASFV. The cut-off value, diagnostic sensitivity (Dsn), and diagnostic specificity (Dsp) of p72-CLIA were 40%, 100%, and 99.6%, respectively, in known background serum, whereas those of p72-MPCLIA were 36%, 100%, and 99.6%, respectively. Thus, both methods show good Dsn, Dsp, and repeatability. However, when analytical sensitivity was evaluated, p72-MPCLIA was more sensitive than p72-CLIA or a commercial enzyme-linked immunosorbent assay. More importantly, p72-MPCLIA reduced the detection time to 15 min and allowed fully automated detection. In summary, p72-MPCLIA showed superior diagnostic performance and offered a new tool for detecting ASFV infections in the future. Key points: • Two chemiluminescence immunoassay (plate-type CLIA and tubular CLIA) methods based on p72 monoclonal antibody (mAb) were developed to detect ASFV antibody. • Both methods show good diagnostic performance (Dsn (100%), Dsp (99.6%), and good repeatability), and p72-MPCLIA detects antibodies against ASFV p72 with high efficiency in just 15 min.
- Open Access
- 3 February 2023
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 14, 1126794
Identification of p72 epitopes of African swine fever virus and preliminary application
African swine fever virus (ASFV) causes a highly lethal hemorrhagic viral disease (ASF) of pigs that results in serious losses in China and elsewhere. The development of a vaccine and diagnosis technology for ASFV is essential to prevent and control the spread of ASF. The p72 protein of ASFV is highly immunogenic and reactive, and is a dominant antigen in ASF vaccine and diagnostic research. In this study, 17 p72 monoclonal antibodies (mAbs) were generated. Epitope mapping by a series of overlapping peptides expressed in Escherichia coli showed that these mAbs recognized a total of seven (1–7) linear B cell epitopes. These mAbs did not show significant neutralizing activity. Epitopes 1 (249HKPHQSKPIL258), 2 (69PVGFEYENKV77), 5 (195VNGNSLDEYSS205), and 7 (223GYKHLVGQEV233) are novel. Sequence alignment analysis revealed that the identified epitopes were highly conserved among 27 ASFV strains from nine genotypes. Preliminary screening using known positive and negative sera indicated the diagnostic potential of mAb-2B8D7. The results provide new insights into the antigenic regions of ASFV p72 and will inform the diagnosis of ASFV.
- 3 February 2023
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 14, 1126794
Open AccessIdentification of p72 epitopes of African swine fever virus and preliminary application
African swine fever virus (ASFV) causes a highly lethal hemorrhagic viral disease (ASF) of pigs that results in serious losses in China and elsewhere. The development of a vaccine and diagnosis technology for ASFV is essential to prevent and control the spread of ASF. The p72 protein of ASFV is highly immunogenic and reactive, and is a dominant antigen in ASF vaccine and diagnostic research. In this study, 17 p72 monoclonal antibodies (mAbs) were generated. Epitope mapping by a series of overlapping peptides expressed in Escherichia coli showed that these mAbs recognized a total of seven (1–7) linear B cell epitopes. These mAbs did not show significant neutralizing activity. Epitopes 1 (249HKPHQSKPIL258), 2 (69PVGFEYENKV77), 5 (195VNGNSLDEYSS205), and 7 (223GYKHLVGQEV233) are novel. Sequence alignment analysis revealed that the identified epitopes were highly conserved among 27 ASFV strains from nine genotypes. Preliminary screening using known positive and negative sera indicated the diagnostic potential of mAb-2B8D7. The results provide new insights into the antigenic regions of ASFV p72 and will inform the diagnosis of ASFV.
- Open Access
- 26 September 2021
- Published by Springer Nature in Virology Journal
- Vol. 18 (1) , 1-10
Development of a competitive chemiluminescence immunoassay using a monoclonal antibody recognizing 3B of foot-and-mouth disease virus for the rapid detection of antibodies induced by FMDV infection
Background: Foot-and-mouth disease (FMD) is a devastating animal disease. Anti-non-structural protein (NSP) antibody detection is very important for confirming suspected cases, evaluating the prevalence of infection, certifying animals for trade and controlling the disease. Methods: In this study, a competitive chemiluminescence immunoassay (3B-cCLIA) was developed for the rapid detection of antibodies against NSPs in different species of livestock animals using the monoclonal antibody (mAb) 9E2 as a competitive antibody that recognizes NSP 3B. Results: The cut-off value (50%), diagnostic sensitivity (Dsn) (97.20%, 95.71%, and 96.15%) and diagnostic specificity (Dsp) (99.51%, 99.43%, and 98.36) of the assay were estimated by testing a panel of known-background sera from swine, cattle and sheep, respectively. The accuracy rate of the 3B-cCLIA was further validated and subsequently compared with that of two commercial diagnostic kits. The early diagnostic results showed that antibodies recognizing NSPs developed later (approximately 1–2 days) than antibodies recognizing structural proteins. Furthermore, anti-NSP antibody presence in animals vaccinated multiple times (false positives), especially cattle and sheep, was confirmed, and the false-positive rate increased with the number of vaccinations. Conclusions: These results indicate that the 3B-cCLIA is suitable for the rapid detection of antibodies against FMDV NSP 3B in a wide range of species.
- 26 September 2021
- Published by Springer Nature in Virology Journal
- Vol. 18 (1) , 1-10
Open AccessDevelopment of a competitive chemiluminescence immunoassay using a monoclonal antibody recognizing 3B of foot-and-mouth disease virus for the rapid detection of antibodies induced by FMDV infection
Background: Foot-and-mouth disease (FMD) is a devastating animal disease. Anti-non-structural protein (NSP) antibody detection is very important for confirming suspected cases, evaluating the prevalence of infection, certifying animals for trade and controlling the disease. Methods: In this study, a competitive chemiluminescence immunoassay (3B-cCLIA) was developed for the rapid detection of antibodies against NSPs in different species of livestock animals using the monoclonal antibody (mAb) 9E2 as a competitive antibody that recognizes NSP 3B. Results: The cut-off value (50%), diagnostic sensitivity (Dsn) (97.20%, 95.71%, and 96.15%) and diagnostic specificity (Dsp) (99.51%, 99.43%, and 98.36) of the assay were estimated by testing a panel of known-background sera from swine, cattle and sheep, respectively. The accuracy rate of the 3B-cCLIA was further validated and subsequently compared with that of two commercial diagnostic kits. The early diagnostic results showed that antibodies recognizing NSPs developed later (approximately 1–2 days) than antibodies recognizing structural proteins. Furthermore, anti-NSP antibody presence in animals vaccinated multiple times (false positives), especially cattle and sheep, was confirmed, and the false-positive rate increased with the number of vaccinations. Conclusions: These results indicate that the 3B-cCLIA is suitable for the rapid detection of antibodies against FMDV NSP 3B in a wide range of species.
- Open Access
- 13 July 2021
- Published by Springer Nature in Research Square
Development of a Competitive Chemiluminescence Immunoassay Using a Monoclonal Antibody Recognizing 3B of Foot-and-mouth Disease Virus for Differentiating Infected From Vaccinated Animals
Background: Foot-and-mouth disease (FMD) is a devastating animal disease. Differentiation of infected from vaccinated animals (DIVA) is very important for confirming suspected cases, evaluating the prevalence of infection, certifying animals for trade and controlling the disease. Methods: In this study, a competitive chemiluminescence immunoassay (3B-cCLIA) for DIVA was developed for the rapid detection of antibodies against non-structural proteins (NSPs) in different species of livestock animals using monoclonal antibody 9E2 as a competitive antibody that recognizes NSP 3B.Results: The cut-off (50%), diagnostic sensitivity (97.20%, 95.71%, and 96.15%) and diagnostic specificity (99.51%, 99.43%, and 98.36) of the assay were estimated by testing a panel of known background sera from swine, cattle and sheep. The accuracy rate of 3B-cCLIA was further validated followed by its comparison with two commercial diagnostic kits. The early diagnostic performance showed that antibodies to NSPs occurred later (about 1–2 days) than antibodies to structural proteins. Furthermore, NSP antibodies present in animals vaccinated multiple times (false-positive), especially in cattle and sheep, were confirmed, and the false-positive rate increased with the number of vaccinations. Conclusions: These results indicated that 3B-cCLIA is suitable to rapidly detect antibodies against FMDV NSP 3B in a wide range of species for DIVA.
- 13 July 2021
- Published by Springer Nature in Research Square
Open AccessDevelopment of a Competitive Chemiluminescence Immunoassay Using a Monoclonal Antibody Recognizing 3B of Foot-and-mouth Disease Virus for Differentiating Infected From Vaccinated Animals
Background: Foot-and-mouth disease (FMD) is a devastating animal disease. Differentiation of infected from vaccinated animals (DIVA) is very important for confirming suspected cases, evaluating the prevalence of infection, certifying animals for trade and controlling the disease. Methods: In this study, a competitive chemiluminescence immunoassay (3B-cCLIA) for DIVA was developed for the rapid detection of antibodies against non-structural proteins (NSPs) in different species of livestock animals using monoclonal antibody 9E2 as a competitive antibody that recognizes NSP 3B.Results: The cut-off (50%), diagnostic sensitivity (97.20%, 95.71%, and 96.15%) and diagnostic specificity (99.51%, 99.43%, and 98.36) of the assay were estimated by testing a panel of known background sera from swine, cattle and sheep. The accuracy rate of 3B-cCLIA was further validated followed by its comparison with two commercial diagnostic kits. The early diagnostic performance showed that antibodies to NSPs occurred later (about 1–2 days) than antibodies to structural proteins. Furthermore, NSP antibodies present in animals vaccinated multiple times (false-positive), especially in cattle and sheep, were confirmed, and the false-positive rate increased with the number of vaccinations. Conclusions: These results indicated that 3B-cCLIA is suitable to rapidly detect antibodies against FMDV NSP 3B in a wide range of species for DIVA.
- Open Access
- 24 January 2021
- Published by Wiley
Development of a competitive chemiluminescence immunoassay using a monoclonal antibody recognizing 3B of foot-and-mouth disease virus for differentiating infected from vaccinated animals
Foot-and-mouth disease (FMD) is a devastating animal disease. Differentiation of infected from vaccinated animals (DIVA) is very important for confirming suspected cases, evaluating the prevalence of infection, certifying animals for trade and controlling the disease. In this study, a competitive chemiluminescence immunoassay (3B-cCLIA) for DIVA was developed for the rapid detection of antibodies against non-structural proteins (NSPs) in different species of livestock animals using monoclonal antibody 9E2 as a competitive antibody that recognizes NSP 3B, which only needs to be washed once and takes 15 min. The cut-off (50%), diagnosis sensitivity (97.20%, 95.71%, and 96.15%) and diagnosis specificity (99.51%, 99.43%, and 98.36) of the assay were estimated by testing a panel of known background sera from swine, cattle and sheep. The accuracy rate of 3B-cCLIA was also validated and compared with that of two commercial diagnostic kits. The early diagnostic performance showed that antibodies to NSPs occurred later (approximately 1–2 days) than antibodies to structural proteins. Furthermore, NSP antibodies present in animals vaccinated multiple times (false-positive), especially in cattle and sheep, were confirmed, and the false-positive rate increased with the number of vaccinations. These results indicated that 3B-cCLIA is suitable to rapidly detect antibodies against FMDV NSP 3B in a wide range of species for DIVA.
- 24 January 2021
- Published by Wiley
Open AccessDevelopment of a competitive chemiluminescence immunoassay using a monoclonal antibody recognizing 3B of foot-and-mouth disease virus for differentiating infected from vaccinated animals
Foot-and-mouth disease (FMD) is a devastating animal disease. Differentiation of infected from vaccinated animals (DIVA) is very important for confirming suspected cases, evaluating the prevalence of infection, certifying animals for trade and controlling the disease. In this study, a competitive chemiluminescence immunoassay (3B-cCLIA) for DIVA was developed for the rapid detection of antibodies against non-structural proteins (NSPs) in different species of livestock animals using monoclonal antibody 9E2 as a competitive antibody that recognizes NSP 3B, which only needs to be washed once and takes 15 min. The cut-off (50%), diagnosis sensitivity (97.20%, 95.71%, and 96.15%) and diagnosis specificity (99.51%, 99.43%, and 98.36) of the assay were estimated by testing a panel of known background sera from swine, cattle and sheep. The accuracy rate of 3B-cCLIA was also validated and compared with that of two commercial diagnostic kits. The early diagnostic performance showed that antibodies to NSPs occurred later (approximately 1–2 days) than antibodies to structural proteins. Furthermore, NSP antibodies present in animals vaccinated multiple times (false-positive), especially in cattle and sheep, were confirmed, and the false-positive rate increased with the number of vaccinations. These results indicated that 3B-cCLIA is suitable to rapidly detect antibodies against FMDV NSP 3B in a wide range of species for DIVA.